NervGen: Spinal Cord Injury Candidate Data Likely by Mid-2025 (NGENF)

I work in the financial sector. My areas of interest are technology, biotechnology, pharmaceutical companies, banking and a little bit of shipping when an actionable deal comes across my radar.

Analyst Disclosure: I/we have an advantageous long position in NGENF stock, either through stocks, options or other derivatives. I wrote this article myself and it expresses my own opinions. I receive no compensation for this (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Request Alpha Disclosure: Past performance does not guarantee future results. No recommendation or advice is given as to whether any investment is suitable for any particular investor. The views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities broker-dealer, investment advisor or investment bank in the United States. Our analysts are third-party authors who include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.